title: Regional Choroidal Thickness Changes in Branch Retinal Vein Occlusion with Macular Edema.
abstract: OBJECTIVE
  To investigate regional changes in choroidal thickness in branch retinal vein occlusion (BRVO) patients with macular edema.
  
  
  METHODS
  Choroidal thickness in the subfoveal, occlusive, and nonocclusive areas in BRVO eyes was measured using enhanced depth imaging by spectral domain optical coherence tomography. The choroidal thickness was compared with the corresponding values both in the fellow eye and in normal controls at baseline. Regional changes in choroidal thickness were then evaluated in the BRVO eyes after intravitreal bevacizumab (IVB) injections.
  
  
  RESULTS
  Regional choroidal thickness was measured in 57 eyes at baseline. The mean choroidal thickness of the occlusive area was significantly higher than that of the nonocclusive, subfoveal, and corresponding areas in the fellow eyes and normal controls (p < 0.001). The choroidal thickness in the occlusive area correlated with the retinal thickness in both the central and occlusive areas (rho = 0.590, p < 0.001, and rho = 0.351, p = 0.011, respectively), but not with visual acuity. After IVB, the choroidal thickness in the occlusive area had decreased significantly (p = 0.004), but remained higher than that of other areas (p < 0.001 and p = 0.026).
  
  
  CONCLUSIONS
  In acute BRVO eyes, the choroid is thicker in the occlusive area. This difference is correlated with the severity of macular edema, but not with visual acuity. Bevacizumab reduces choroidal thickness, but does not restore normal values.
authors: Department of Ophthalmology, Pusan National University Yangsan Hospital, Yangsan, South Korea.
authors: Kyung Ho
authors: KH
authors: Kim
authors: Dong Hyun
authors: DH
authors: Lee
authors: Jae Jung
authors: JJ
authors: Lee
authors: Sung Who
authors: SW
authors: Park
authors: Ik Soo
authors: IS
authors: Byon
authors: Ji Eun
authors: JE
authors: Lee
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000068258:Bevacizumab / Q000627:therapeutic use; D002829:Choroid / Q000473:pathology*; D005260:Female; D006801:Humans; D058449:Intravitreal Injections; D008269:Macular Edema / Q000150:complications* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009929:Organ Size; D012160:Retina / Q000473:pathology; D012170:Retinal Vein Occlusion / Q000150:complications* / Q000188:drug therapy; D012189:Retrospective Studies; D041623:Tomography, Optical Coherence; D042461:Vascular Endothelial Growth Factor A / Q000037:antagonists & inhibitors; D014792:Visual Acuity / Q000502:physiology
chemical_list: D020533:Angiogenesis Inhibitors; C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab